Sagility Q1 FY27: strong steady-state growth, stable margins, and a new quality-tech lever

Sagility opened FY27 with a solid steady-state quarter. For Q1 FY27 (quarter ended June 30, 2026), revenue from operations was INR 19,635 million (INR 1,963.5 crore), up 27.6% year on year. Adjusted EBITDA rose 27.9% to INR 4,716 million (INR 471.6 crore), keeping margins steady at 24.0%. Adjusted PAT increased 35.1% to INR 2,697 million (INR 269.7 crore), translating into a 13.7% margin.

The quarter matters because it came right after the seasonally strong Open Enrollment period, which typically boosts Q3 and Q4. Even with that seasonal tailwind fading, management highlighted steady-state momentum, citing growth led by expansion within existing clients and scaling of FY26 new client additions.

What drove Q1: steady-state growth and client expansion

Sagility described Q1 growth as being driven by two levers. First, deeper penetration within existing clients through expansion opportunities and new statements of work. Second, an increasing contribution from clients added in FY26. In Q1, the company signed USD 35.3 million of steady-state ACV, across 18 existing clients and 1 new logo.

The vertical mix remains highly concentrated in payer operations. In Q1 FY27, payers contributed 89.6% of revenue, while providers contributed 10.4%.

Operationally, the company reported improved working capital. Q1 operating cash flow was INR 3,161 million (INR 316.1 crore) with a conversion of 69.9%. Days sales outstanding improved to 80 days.

CareSeed: adding quality-tech depth and mid-market reach

A key strategic event in the quarter was the acquisition of CareSeed, a U.S.-based healthcare analytics company founded in 2012 and headquartered in Kansas City, Missouri. CareSeed’s solutions include Forecast (HEDIS reporting and quality analytics) and Harvest (cloud-based medical record review, chart abstraction, and supplemental data capture).

Sagility disclosed the following CareSeed metrics:

• CY25 revenue of about USD 5.1 million
• About 95% recurring revenue
• CY25 EBITDA margin of 31.4%
• 30 small and mid payer clients
• 14 team members

The acquisition thesis was positioned around capability, technology, cross-sell, and talent. Capability-wise, management highlighted strengthening its quality proposition for Medicare Advantage plans across HEDIS, CMS Stars, and care-gap orchestration. On technology, CareSeed’s NCQA-certified platforms were positioned as enabling a shift from retrospective quality reporting toward integrated and AI-led quality operations.

From a market expansion standpoint, Sagility stated it added 26 new client groups via the acquisition (with the investor deck also noting 30 clients at CareSeed, including overlaps). Management also framed CareSeed as widening Sagility’s reach in the mid and small payer segment and creating immediate cross-sell opportunities, including the ability to sell abstraction and broader care operations services on top of the CareSeed platform.

Margin guardrails: wage hikes, FX moves, and seasonality

Despite a strong operating quarter, the call made it clear that FY27 will have identifiable margin cross-currents.

First, statutory minimum wages increased in Karnataka and Telangana, with the company quantifying an in-quarter impact of INR 70 million in Q1. Management estimated the full-year impact at about 120 basis points on adjusted EBITDA margin for FY27. The quarter also included a one-time exceptional item of INR 151 million related to past service cost toward gratuity and compensated absences arising from the wage revisions.

Second, Q1 included a reported forex loss of INR 283 million driven by FX hedges, which affected reported EBITDA and profit but is separated out in the adjusted performance measures.

Third, seasonality remains structural. The company reiterated that Q3 and Q4 typically carry seasonal revenues related to Open Enrollment and AEP. Q4 FY26 included INR 2,260 million of seasonal revenue; Q1 FY27 did not.

Against this backdrop, management reiterated its full-year margin guidance of 24% to 25%, explicitly stating this is after absorbing the estimated 120 basis points impact from minimum wage increases.

Guidance and investor watchpoints

Management reiterated FY27 guidance of low double-digit organic growth in constant currency. It also guided to adjusted EBITDA margins of 24% to 25% for FY27. The company indicated that it expects greater visibility into the full-year outlook by the end of Q2, especially as it moves closer to the Open Enrollment season.

A few points investors will likely track from here:

Client concentration remains high. On a TTM basis ended June 2026, the top 3 clients contributed 60.1% of revenue, the top 5 contributed 70.1%, and the top 10 contributed 84.1%.

The wage hike impact is concentrated because a large part of Sagility’s India delivery footprint is in Bengaluru and Hyderabad. Management also clarified that minimum wage revisions create cascading impacts beyond the employees directly at statutory thresholds.

Cross-sell execution is a key part of the CareSeed and BroadPath logic. While management pointed to active pipelines and cross-sell conversations, it did not quantify conversion into revenue yet.

Takeaway

Sagility’s Q1 FY27 was a strong steady-state quarter. Growth was robust, margins held at 24%, and cash generation remained healthy with improving DSO. The acquisition of CareSeed adds a technology-led wedge into quality operations, along with a meaningful set of mid and small payer relationships.

The next few quarters will test how well the company can absorb a quantified statutory wage headwind while staying within the 24% to 25% margin band, and how quickly the CareSeed platform plus services narrative translates into scaled cross-sell outcomes.